The Uganda Cancer Institute (UCI) has made a significant advancement in cancer care with the acquisition of a state-of-the-art Symbia Intevo Bold Eco SPECT-CT scanner.
This high-tech medical imaging equipment, valued at Shs15 billion, is set to revolutionize cancer diagnostics and therapeutic interventions by providing unparalleled precision in detecting and monitoring malignancies, particularly in challenging anatomical regions such as bone tissue.
Transformative Impact of the SPECT-CT Scanner
The newly acquired SPECT-CT (Single Photon Emission Computed Tomography-Computed Tomography) scanner is a hybrid imaging modality that combines functional and anatomical imaging, allowing oncologists to localize and characterize tumors with exceptional accuracy.
According to Dr. Jackson Orem, Executive Director of UCI, this technological advancement represents a pivotal step toward the establishment of a Division of Molecular Imaging and Therapy, solidifying the institute’s role as a center of excellence in oncology across the African continent.
Dr. Godfrey Osinde, Head of the Nuclear Medicine Department at UCI, emphasized the scanner’s transformative potential.
“This innovative technology enables precise detection and characterization of cancer cells, thereby facilitating early diagnosis and targeted therapeutic approaches such as Targeted Radionuclide Therapy (TRT),” Dr. Osinde explained.
TRT employs radioisotopes to selectively target and destroy malignant cells while preserving healthy tissue, a significant improvement over conventional treatment modalities.
“With this advancement, we are offering world-class oncological care right here in Uganda,” he added.
Advancements in Molecular Imaging and Therapy
The acquisition of the SPECT-CT scanner is part of a broader initiative spearheaded by UCI to establish a comprehensive Division of Molecular Imaging and Therapy, also referred to as the Positron Emission Tomography (PET) Centre.
This initiative is unfolding in three well-structured phases to enhance Uganda’s capacity in nuclear medicine and radiopharmaceutical applications.
Phase I of the project, currently 95% complete, has focused on strengthening radiotherapy and nuclear medicine infrastructure.
In addition to the SPECT-CT scanner, the UCI Radiotherapy Centre is now equipped with TrueBeam Linear Accelerators, which deliver high-precision radiation therapy, and advanced treatment planning systems.
These developments establish UCI as a regional leader in comprehensive cancer management.
Another key component of the new division is the integration of a radiopharmacy facility featuring state-of-the-art hot labs and clean room infrastructure.
These facilities are essential for the production and quality control of radiopharmaceuticals, the specialized compounds used in molecular imaging and TRT.
The ability to produce radiopharmaceuticals locally ensures greater accessibility to precise and individualized cancer treatment, which remains scarce in many African nations.
Future Developments in Cancer Care
With the completion of Phase I, UCI is preparing for the launch of Phase II, scheduled to commence in August 2025.
This ambitious expansion will include the establishment of an isotope production facility, a cold-kit production unit for radiopharmaceutical synthesis, and advanced research laboratories.
Additionally, Phase II will introduce a vivarium for preclinical research, PET scan suites, interventional radiology services, and endoscopy units, further expanding UCI’s diagnostic and treatment capabilities.
Dr. Orem expressed confidence in the transformative potential of these initiatives.
“With unwavering government support, we are creating a facility that meets and exceeds global standards. This division is a game-changer, not just for Uganda but for the entire continent,” he stated.
“By integrating cutting-edge molecular imaging and targeted therapies, we are not only enhancing patient care but also advancing research and training in oncology.”
A New Era in Cancer Management
The continued development of the Division of Molecular Imaging and Therapy at UCI marks a milestone in Africa’s fight against cancer.
With access to precision oncology, innovative therapies, and groundbreaking research capabilities, Uganda is positioning itself as a leader in cancer diagnosis and treatment.
The introduction of the SPECT-CT scanner is just the beginning of a comprehensive strategy to ensure that Ugandan patients receive the highest standard of care while setting a precedent for cancer care across the region.
As these advancements unfold, UCI remains committed to bridging the gap in cancer treatment by leveraging technological innovations, enhancing research collaborations, and fostering medical expertise in nuclear medicine.
With these efforts, Uganda is paving the way for a future where early detection, targeted therapy, and personalized cancer care become the standard, not the exception.
